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Abstract 
Superior vena cava syndrome (SVCS) is a relatively common sequela of mediastinal malignancies and may cause 
significant patient distress. SVCS is a medical emergency if associated with laryngeal or cerebral edema. The etiologies 
and management of SVCS have evolved over time. Non‑malignant SVCS is typically caused by infectious etiologies 
or by thrombus in the superior vena cava and can be managed with antibiotics or anti‑coagulation therapy, respec‑
tively. Radiation therapy (RT) has long been a mainstay of treatment of malignant SVCS. Chemotherapy has also been 
used to manage SVCS. In the past 20 years, percutaneous stenting of the superior vena cava has emerged as a viable 
option for SVCS symptom palliation. RT and chemotherapy are still the only modalities that can provide curative treat‑
ment for underlying malignant etiologies of SVCS. The first experiences with treating SVCS with RT were reported in 
the 1970’s, and several advances in RT delivery have subsequently occurred. Hypo‑fractionated RT has the potential to 
be a more convenient therapy for patients and may provide equal or superior control of underlying malignancies. RT 
may be combined with stenting and/or chemotherapy to provide both immediate symptom palliation and long‑term 
disease control. Clinicians should tailor therapy on a case‑by‑case basis. Multi‑disciplinary care will maximize treat‑
ment expediency and efficacy.
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Background
Superior vena cava syndrome (SVCS), a clinical mani-
festation arising from compression of the thin-walled 
superior vena cava (SVC), was first described by William 
Hunter in 1757 and can be caused by a variety malignan-
cies (Hunter and Johnston 1757). SVCS is a significant 
disorder affecting up to 10  % of small cell lung cancer 
(SCLC) patients and 2–4  % of all lung cancer patients 
(Wan and Bezjak 2010). The prognosis of SVCS caused by 
malignancies is primarily determined by the tumor type 
(Yu et al. 2008). Traditionally, malignant SVCS has been 
considered to be an indication for emergent intervention, 
typically with radiation therapy (RT). However, accumu-
lating evidence has suggested that accurate diagnosis and 
biopsy should precede emergent therapeutic interven-
tion in most cases (Yu et al. 2008). Timely and effective 
intervention aimed at treating the malignant cause of this 
syndrome can relieve significant suffering and improve 
SVCS patients’ quality of life.
Anatomy and physiology
The SVC carries approximately one-third of the venous 
return to the heart. Situated slightly to the right of mid-
line and coursing through the superior and middle medi-
astinum, the SVC is the major drainage outlet for venous 
return from the head, arms, and upper torso. Despite its 
high flow volume, the SVC is quite distensible and can be 
compressed by an adjacent mass originating in the mid-
dle or anterior mediastinum, the right paratracheal or 
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precarinal lymph node stations, or the right lobe bron-
chus (Wan and Bezjak 2010; Wilson et  al. 2007). Right-
sided masses are more likely to cause SVCS, presumably 
due to the anatomic location of the SVC (Sculier et  al. 
1986). Rarely, a thrombus can occlude the SVC even in 
the absence of an external mass.
The superior and middle mediastinum is an anatomi-
cally confined space populated by a large number of 
lymph nodes. The SVC is thin walled and is opened by 
relatively low venous pressure, making it particularly 
susceptible to compression by adjacent masses (Koetters 
2012). In the event of SVC obstruction, venous pressure 
in collateral vessels increases and, over time, a collateral 
blood-flow network develops (Lacout et al. 2012). Many 
different vessels may enlarge in response to the increased 
blood pressure, including the azygos, the hemiazygos, 
intercostal, mediastinal, paravertebral, thoracoepigas-
tric, internal mammary, thoracoacromioclavicular, and 
anterior chest wall veins (Eren et  al. 2006). The azygos 
vein may connect the SVC and the inferior vena cava 
(IVC) directly, so SVC obstructions below the insertion 
of the azygos vein typically result in more severe symp-
toms of SVCS (Stanford et  al. 1987). Typically, multiple 
weeks are required for development of sufficiently large 
collateral network to accommodate the blood flow that 
normally passes through the SVC (Kim et  al. 1993; Tri-
gaux and Van Beers 1990). If SVC occlusion occurs rela-
tively slowly, then patients may remain asymptomatic 
as the collateral network is able to grow apace with the 
increasing SVC obstruction. In contrast, rapidly devel-
oping, complete or near-complete SVC obstructions can 
cause a variety of sequelae, including dyspnea; swelling of 
the neck, trunk, upper extremities and face; chest pain; 
collateral venous distension; plethora; dysphagia; and 
hoarseness (Armstrong et al. 1987; Rice et al. 2006; Chen 
et al. 1990; Mineo et al. 1999).
Increased venous pressure can lead to marked edema 
of the upper body including the face, neck, upper extrem-
ities. This can cause significant patient discomfort and, 
in severe cases, narrowing of the upper respiratory tract 
secondary to nasal and laryngeal edema (Baker and 
Barnes 1992). Rarely, cerebral edema may develop and 
necessitate emergent treatment (Baker and Barnes 1992; 
Sofue et al. 2013; Taguchi et al. 2011). Death is very rarely 
caused by SVCS. In one series of 1986 patients with 
SVCS, only 1 death was reported (Ahmann 1984).
Etiologies
Common causes for masses that can impinge on the 
SVC include enlarged paratracheal lymph nodes of 
malignancies, lymphoma, thymoma, inflammatory 
processes, and aortic aneurysms. Before antibiotics 
came into widespread use, infectious etiologies were 
a common cause of SVCS. Specifically, aortic aneu-
rysms due to tertiary syphilis were frequent (Schech-
ter 1954). More recently, however, tertiary syphilis has 
become rare, while the overall incidence of malignan-
cies has risen due to the increased average lifespan of 
our population. In the 1970s and 1980s, malignancies 
caused 78–93 % of SVCS (Chen et al. 1990; Parish et al. 
1981). In the past 20  years, intravascular devices such 
as catheters and pacemakers have become much more 
common (Cheng 2009). Thrombi associated with these 
devices have emerged as a significant cause of SVCS, 
accounting for up to 28  % of cases of SVCS in some 
reports (Rice et al. 2006a; b). Despite the recent rise in 
thrombus-driven SVCS, malignancies remain the most 
common cause of SVCS. Furthermore, we may pre-
sume that, as surgical experience and expertise with 
implantable devices matures, the majority of SVCS will 
continue to be malignancy-derived and the percentage 
of SVCS due to malignancy may actually rise in subse-
quent decades. As seen in Table 1, among the malignant 
causes of SVCS, non-small cell lung cancer (NSCLC) 
(22–57  %), small-cell lung cancer (SCLC) (10–39  %), 
and lymphoma (1–27  %) are by far the most common 
causes (Armstrong et  al. 1987, 2006; Chen et  al. 1990; 
Yellin et  al. 1990; Schraufnagel et  al. 1981; Nicholson 
et al. 1997; Hohloch et al. 2014).
Clinical evaluation
SVCS presents with signs and symptoms that may be 
readily identified on clinical evaluation (Cheng 2009). The 
most common symptoms of SVCS include neck swelling 
(100 %), dyspnea (54–83 %), swelling of the trunk and/or 
upper extremities (38–75  %), facial swelling (48–82  %), 
chest pain (15  %), cough (22–58  %), dilated chest vein 
collaterals (38 %), weight loss (10–31 %), jugular venous 
distension (27 %), phrenic nerve paresis (16.2 %), plethora 
(13 %) and dysphagia (10–13 %) (Armstrong et al. 1987; 
Rice et  al. 2006a; Chen et  al. 1990; Mineo et  al. 1999). 
More rarely reported symptoms include hoarseness, 
headache, confusion, dizziness, night sweats, hypoxia, 
hyponatremia, and syncope (Wan and Bezjak 2010; Rice 
et al. 2006a; Mineo et al. 1999). Symptoms typically have 
a gradual onset. In general, the faster the onset of symp-
toms the more severe the symptoms, as slowly advancing 
obstruction of the SVC allows time for collateral circula-
tion development.
The most common findings on physical exam include 
edema of the face, neck, trunk, and upper extremities as 
well as collateral venous distension of the neck and the 
anterior chest wall. More rarely, plethora or cyanosis can 
be observed. Symptoms may include dyspnea, dysphagia, 
hoarseness, stridor, cough, and chest pain. Symptoms 
associated with cerebral edema can include neurologic 
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symptoms such as headaches, confusion, dizziness, 
obtundation, and mental status changes (Yu et al. 2008).
To assist in determining the urgency of intervention 
and tracking progression of symptoms, a classification 
scheme has been proposed for grading SVCS accord-
ing to symptom severity (Lonardi et al. 2002). This clas-
sification schema includes parameters such as degree 
of cerebral edema, laryngeal edema, and hemodynamic 
compromise to differentiate between life-threatening 
(grade 4), severe (grade 3), and non-life threatening 
(grade 0–2) (Yu et al. 2008). Another scaled scoring sys-
tem, the Kishi score, has been developed to assist in mak-
ing the decision to initiate stent therapy. The Kishi score 
system incorporates neurological, laryngeal, facial, and 
cardiovascular signs and symptoms (Kishi et  al. 1993). 
As seen in Table  2, a score of 4 or higher using the 
Kishi scoring system indicates a need for percutaneous 
stenting.
Imaging
Chest imaging is an important diagnostic tool that can 
frequently be used to find the abnormality underlying 
SVCS (Lacout et  al. 2012). 84  % of SVCS patients have 
abnormal chest X-rays, with 64 % demonstrating widen-
ing of the superior mediastinum and 26  % demonstrat-
ing pleural effusion (Parish et  al. 1981). Ultrasound can 
be used to rule out venous thrombus, but, due to the 
interposition of overlying ribs between the probe and 
the mediastinum, ultrasound cannot be used to directly 
image the SVC. However, Doppler ultrasound can reveal 
flow reversal in the internal thoracic vein, which is indic-
ative of SVC obstruction (Spiro et  al. 1983). Similarly, 
Doppler ultrasound can show a resolution of blockage 
and return to normal flow after successful treatment 
(Lacout et  al. 2012). Computed tomography (CT) scans 
and magnetic resonance imaging (MRI) studies are com-
monly used in initial evaluation of SVCS and can reveal 
SVC blockage prior to symptom development (Uberoi 
2006).
Contrast-enhanced spiral or multi-slice CT imaging 
may be used to elucidate the cause as well as the extent 
of venous obstruction. These imaging modalities may 
reveal distended collateral vasculature, which strongly 
suggest SVCS with sensitivity of 96  % and specificity of 
92  % (Kim et  al. 1993). Contrast-enhanced CT imaging 
can also be used to elucidate physical characteristics of 
the obstruction in preparation for stent insertion (Spiro 
Table 1 Etiologies of superior vena cava syndrome
Malignant and non-malignant causes of superior vena cava syndrome
Etiology (Rice et al. 2006a; Chen 
et al. 1990; Mineo et al. 1999; 
Schraufnagel et al. 1981; Nichol-
son et al. 1997; Hohloch et al. 
2014; Lonardi et al. 2002)
Prevalence (%) (Rice et al. 2006a; 
Chen et al. 1990; Mineo et al. 
1999; Schraufnagel et al. 1981; 
Nicholson et al. 1997; Hohloch 
et al. 2014; Lonardi et al. 2002)
Malignant
Non‑small cell lung cancer 22–57




























Table 2 Kishi Scoring system
Presence of any of the symptoms in the left column give the points indicated in 
the right column. The total points are added to together. A score of 4 or higher 
indicates a need for percutaneous stent placement
Clinical signs (Lacout et al. 2012; Kishi et al. 1993) Weighting
Neurological signs
Awareness disorders or coma 4
Visual disorders, headache, vertigo or memory disorders 3
Mental disorders 2
Malaise 1
Thoracic or pharyngeal‑laryngeal signs
Orthopnea or laryngeal edema 3
Stridor, dysphagia or dyspnea 2
Coughing or pleurisy 1
Facial signs
Lip edema, nasal obstruction or epistaxis 2
Facial edema 1
Vessel dilation
Neck, face or arms 1
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et  al. 1983). A classification schema of SVC stenosis 
based on CT findings has been proposed, and it may 
be useful for determining prognosis and utility of stent 
insertion (Lacout et al. 2012). If higher resolution imag-
ing is needed, multi-detector CT can be used to provide 
3-dimensional anatomic detail of collateral vasculature 
(Eren et al. 2006). Lastly, for patients who cannot tolerate 
the long duration of MRI, CT venography may be con-
sidered. Complications of venography are rare and mild, 
including bleeding from the site easily controlled by a few 
minutes of direct pressure (14 %) (Rice et al. 2006a) and 
transient respiratory distress (0.5 %) (Ahmann 1984).
Contrast-enhanced magnetic resonance (MR) venogra-
phy is a highly sensitive and accurate diagnostic modality, 
shown to be up to 100 % sensitive and specific for diag-
nosing central venous abnormalities (Davenport et  al. 
1976; Rachapalli and Boucher 2014). Unfortunately, it 
is expensive and time-consuming, and dyspneic SVCS 
patients may have difficulty remaining supine for the 
entire imaging process. For patients allergic to contrast 
dye or with difficult venous access, standard MRI is often 
sufficient (Cheng 2009).
Superior vena cavography is generally carried out 
before stenting, and is considered the gold standard for 
detecting thrombotic obstruction in the SVC and dem-
onstrating the extent of thrombus formation (Uberoi 
2006). It has been shown to be better than conventional 
CT for visualizing opacified collateral vessels, exten-
sion of thrombi into peripheral vessel, and the degree of 
obstruction (Cheng 2009). It is less useful for revealing 
causes of obstruction other than thrombus.
Histology
Imaging may distinguish between masses and thrombi as 
causes of SVCS, but, in the case of an obstructing mass 
where suspicion for malignancy is high, biopsy and his-
tological studies are required to determine the type of 
malignancy. One study revealed that up to 59 % of SVCS 
patients present without a previous cancer diagnosis 
(Schraufnagel et al. 1981). Minimally invasive techniques 
such as sputum cytology, pleural fluid cytology, or super-
ficial lymph node biopsy can be used to diagnose up to 
two-thirds of malignancies (Schraufnagel et al. 1981). To 
diagnose the remaining one-third, invasive procedures 
such as bronchoscopy, mediastinoscopy, mediastinot-
omy, thoracotomy, and thoracoscopy may be required 
to classify primary tumor type. Bone marrow biopsies 
may be able to provide a diagnosis as well as determine 
the stage of malignant lymphoma, and, less commonly 
used in current medical practice, small cell lung cancer. 
Most studies report low rates of complication and high 
diagnostic value in mediastinal procedures (Rice et  al. 
2006a; Mineo et al. 1999). Major bleeding and respiratory 
distress rarely occurred after thoracotomy, mediastinos-
copy, or bronchoscopy (Ahmann 1984).
Management
Figure 1 provides a management algorithm that may be 
used by practitioners to guide clinical decision making.
Emergent palliation
In select cases, SVCS may be life threatening and requires 
emergent treatment. If laryngeal edema causing laryngeal 
constriction or cerebral edema is present, these medi-
cal emergencies require prompt management and rapid 
treatment of the underlying cause of SVCS may be indi-
cated (Baker and Barnes 1992; Sofue et  al. 2013; Tagu-
chi et al. 2011). These clinical SVCS sequelae may cause 
long-term morbidity or mortality if left untreated, and 
empiric treatment with radiation, stenting, and/or chem-
otherapy may be indicated even before biopsy results 
become available. Similarly, if clinical and radiographic 
evidence reveals a rapidly growing malignancy with a 
high likelihood of invading other critical thoracic struc-
tures, then prompt treatment to retard cancer growth is 
indicated (Devita Jr 1997). To minimize respiratory and 
cardiac complications in patients who present with tra-
cheal obstruction or pericardial effusion, stenting and 
immediate RT may be recommended before attempting 
invasive procedures (Sculier et al. 1986).
As mentioned above, multiple scoring systems have 
been developed to assist practitioners in classifying the 
urgency of SVCS cases. In Yu et al.’s classification scheme, 
grade 4 SVCS indicates life-threatening disease due to one 
or more of the following: “significant cerebral edema (con-
fusion, obtundation) or significant laryngeal edema (stri-
dor) or significant hemodynamic compromise (syncope 
without precipitating factors, hypotension, renal insuf-
ficiency).” Although only 5  % of SVCS patients present 
with grade 4 disease, any of the aforementioned compli-
cations would be an indication for emergent venogram, 
stent placement, and thrombolytic therapy if indicated 
(Yu et al. 2008). Of note, immediate RT is not indicated as 
first line treatment in emergent cases of SVCS if stenting 
is feasible, as stenting has been shown to provide faster 
symptom resolution (Nicholson et al. 1997).
Urgent palliation
Previously, all case of SVCS were considered medi-
cal emergencies. More recently, numerous reviews 
have shown no association between symptom dura-
tion and long-term treatment outcomes for most cases 
of SVCS when using chemotherapy, radiation, or stent-
ing (Schraufnagel et  al. 1981; Mose et  al. 2006; Khan 
et  al. 2014; Gauden 1993; Ampil et  al. 2012). Further-
more, obtaining an accurate histologic diagnosis prior to 
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starting RT allows for optimum treatment of the causa-
tive malignancy (Ampil et al. 2012; Kvale et al. 2007).
For SVCS caused by an infectious etiology, antibiotics 
should be the first line of treatment. In cases of throm-
bus-driven SVCS, anticoagulation therapy is first-line 
treatment and may effective in up to 88 % of patients if 
anticoagulation is initiated within 5  days of thrombus 
development (de Jager et al. 2013; Gray et al. 1991). Some 
experts recommend continuing anti-coagulation ther-
apy indefinitely after an incident of SVC occlusion by a 
thrombus (Cheng 2009).
Although they have no effect on the underlying etiol-
ogy of SVCS, several maneuvers are available for symp-
tom palliation in significantly distressed patients. The 
underlying goal of these maneuvers is to reduce hydro-
static pressure in the upper half of the body. To that end, 
the patient should assume a seated position or at least 
elevate his head (Cheng 2009). Additionally, fluid restric-
tion, diuretics and/or supplemental oxygen may be con-
sidered (Wan and Bezjak 2010; Wilson et al. 2007).
Radiation with or without concomitant steroids or 
chemotherapy was long considered to be the quickest 
and most efficacious option for long-term symptom 
relief. SVCS symptom improvement may begin as early 
as 3–9  days after starting RT, although response times 
of more than 30  days have been reported (Armstrong 
et  al. 1987; Yellin et  al. 1990; Schraufnagel et  al. 1981; 
Nicholson et al. 1997; Mose et al. 2006; Ostler et al. 1997; 
Davenport et  al. 1978). In the past decade, advances 
in interventional radiology have brought percutane-
ous stenting to the forefront of SVCS care. Placement 
of a percutaneous stent can give symptom relief start-
ing as soon as 0–72  h after the procedure (Watkinson 
et  al. 2008; Hennequin et  al. 1995; Rosch et  al. 1992). 
As detailed in Table  3, RT, chemotherapy, and stent-
ing all offer unique advantages and disadvantages for 
SVCS patients, and practitioners should choose the most 




RT has long been considered a mainstay of SVCS treat-
ment (Wan and Bezjak 2010; Wilson et  al. 2007; Ostler 
Fig. 1 Management algorithm for SVCS. A broad overview that may be used to guide clinical decision making
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et al. 1997; Egelmeers et al. 1996). Although stent place-
ment has recently emerged as a viable palliative option 
in many case of SVCS, RT remains an important part of 
treatment in most cases of SVCS and may be used as sole 
treatment in select cases.
RT typically does not achieve complete relief of SVC 
obstruction. In one review, post-RT venography showed 
a normal SVC flow in only 11.1 % of patients, and post-
mortem analysis demonstrated completely or partially 
patent SVCs in only 24.2 % of patients. Despite this, the 
clinical response rate in this cohort was roughly 50–70 % 
(Ahmann 1984). Decreased tumor bulk after RT probably 
results in an increased capacity for collateral circulation, 
and may account for the discrepancy between symptom 
improvement and SVC re-patency after RT (Wilson et al. 
2007).
The first experiences with RT for SVCS were published 
in the 1970s. Relatively high daily doses of 400  centiG-
ray (cGy) to the mediastinum were delivered for the first 
3 days followed by 150 cGy fractions to a total of 3000–
5000  cGy (Davenport et  al. 1976). Patients reported a 
subjective 77 and 91 % response rate at 3–4 and 7 days 
after treatment, and an objective response rate of 66 and 
89 % was observed 3–4 and 7 days after treatment (Dav-
enport et al. 1978). Given the high response rate and the 
relatively rapid time to symptom palliation, RT became 
the treatment of choice for patients with SVCS.
A retrospective study of 125 SVCS patients treated 
with RT from 1965 to 1984 found that 83 % of patients 
receiving high initial dose RT responded to treatment 
while 78  % of patients receiving conventional initial 
dose therapy responded to treatment. 70  % of patients 
treated with high initial dose RT (defined in this study 
as 300–400 cGy for 3 fractions at the beginning of ther-
apy) showed a response within 2 weeks while only 56 % 
of patients receiving conventional fractionation RT up 
front experienced a response in that timeframe, but the 
difference was not statistically significant. Lastly, a dose-
dependent response to RT was observed. Only 50  % of 
patients receiving less than 20 Gy responded to therapy, 
while 87 % of patients receiving greater than 20 Gray (Gy) 
responded to treatment. Dysphagia, the most common 
side effect, was experienced by 26  % of patients. Only 
13 % of patients experienced recurrent SVCS, but 54 % of 
NSCLC and 57 % of SCLC patients went on to relapse at 
other sites. Of note, 8.8 % of all patients who received RT 
to the supraclavicular lymph nodes recurred in that area, 
compared to 33 % of patients who did not receive RT to 
the supraclavicular area and went on to progress at that 
site. The median survival of all SVCS patient included in 
the review was 5.5  months, 1-year overall survival (OS) 
was 24 %, and 5-year OS was 9 % (Armstrong et al. 1987).
A meta-analysis of prospective and retrospective stud-
ies from 1983 to 1997 found that, for patients with SCLC, 
radiation alone provided a 77.6 % rate of complete SVCS 
symptom relief and combined chemoradiation resulted 
in an 83.3 % symptom relief rate. In NSCLC patients, the 
symptom relief rate was 63.0 % for radiation alone versus 
31.3 % with combined chemoradiation (Rowell and Glee-
son 2001).
A Belgian experience treating 34 SVCS patients from 
1986 to 1993 has been reported. Based on the patient’s 
performance status, the obstructing mass was treated 
with doses ranging from 30  Gy in 9 fractions to 54  Gy 
in 24 fractions. Patients with poor performance status 
received 5 fractions of 4  Gy at the onset of treatment, 
while patients with good performance status received 
2 fractions of 4  Gy at treatment onset. After this initial 
treatment schema, patients were re-evaluated and treated 
with continued rapid high-dose irradiation or switched 
to a more conventional 2 Gy per fraction dose regimen. 
79  % of patients who received 4  Gy daily responded to 
therapy compared to 67 % of patients who received 2 Gy 
daily. Four patients received split course therapy; they did 
not demonstrate a difference in response rate or survival 
compared to patients who received continuous ther-
apy. Of note, patients with NSCLC responded to treat-
ment more rapidly than patients with SCLC. In general, 
patients who responded rapidly to therapy had a better 
OS (Egelmeers et al. 1996).
There have been no randomized trials comparing RT 
fractionation schemes, and even retrospective evidence 
Table 3 Comparison of treatment modalities
Properties of various treatment modalities used in superior vena cava syndrome
Time to symptom relief % Chance of partial  
symptom relief




Radiation Therapy 3–30 days (Armstrong et al. 1987; Mose 
et al. 2006; Ostler et al. 1997; Davenport 
et al. 1978; Rodrigues et al. 1993)
56–96 (Armstrong et al. 1987;  
Rodrigues et al. 1993)
Yes Low
Chemotherapy 1–2 weeks (Rowell and Gleeson 2001) 59–77 (Rowell and Gleeson 2001) Yes Low
Stent placement 0–72 h (Hennequin et al. 1995; Rosch  
et al. 1992)
80–95 % (Uberoi 2006) Yes 3–4 % (Uberoi 2006)
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is limited (Chan et  al. 1997). The more effective frac-
tionation schemes involve giving relatively large doses 
of 3–4  Gy for the first 2–5 fractions followed by con-
ventional, 2 Gy fractionation to a total dose of 30–50 Gy 
(Armstrong et al. 1987; Davenport et al. 1978; Egelmeers 
et al. 1996). The initial radiation field should encompass 
gross disease and adjacent lymph node beds, and may be 
altered during treatment as appropriate given changing 
symptoms and/or tumor size (Wilson et al. 2007).
Definitive radiotherapy
For select SVCS, treatment with curative intent may 
be considered. Among others, those with stage II or III 
NSCLC, limited stage SCLC, and those with low grade 
lymphoma may be candidates for definitive single or 
multi-modality treatment. In these cases practitioners 
should follow typical protocols for treating the lesion 
in question, giving definitive doses of radiation as indi-
cated by the tumor type and anatomic location. Treat-
ment teams may wish to consider stent placement prior 
to definitive RT for symptoms palliation during the ini-
tial days of RT. As with any bulky tumor, masses causing 
SVCS may shrink dramatically during definitive RT, and 
repeat planning mid-treatment may be indicated. Strat-
egies of starting with initial therapy with higher doses 
3–4 Gy for first 2–3 days, followed by resumption of con-
ventional fractionation of 1.8–2 Gy/day to deliver defini-
tive total dose can also be considered (Brady and Perez 
2007).
Consideration of hypofractionated radiation therapy
As discussed above, lung cancer is the most common 
cause of SVCS, and radiation plays an important role in 
both palliative and definitive treatment. Several stud-
ies have demonstrated that hypofractionated regimens 
can have equivalent outcomes and toxicity profiles to 
more conventionally fractionated treatment courses in 
NSCLC (Sundstrøm et al. 2004; Cheung et al. 2014; Din 
et al. 2013). Additionally, stereotactic body RT, or SBRT, 
has been shown to produce very high rates of local tumor 
control in NSCLC and to be well tolerated and efficacious 
for a variety of lung malignancies (Robinson et al. 2009; 
Timmerman et al. 2010).
Often, patients who present with SVCS have a con-
tracted life expectancy due to their underlying disease 
burden. For these patients, 3–4  weeks of daily treat-
ments may be bothersome and are certainly not practi-
cal. In the interest of improving patient convenience 
while maintaining therapeutic outcomes, a shorter frac-
tionation scheme was developed and used at University 
Hospital in Amsterdam, The Netherlands. A retrospec-
tive study of 39 SVCS patients treated with 2 different 
hypofractionated RT courses from 1986 to 1992 was 
performed to compare the efficacy and side effects of the 
different fractionation schemes.  25 patients received a 
total of 24 Gy in 3 weekly fractions and 7 patients were 
treated to a total of 16 Gy in 2 weekly fractions. 56 % of 
patients treated to 24 Gy had a complete response, while 
only 28  % of patients treated to 16  Gy had a complete 
response. 96 % of the patients treated to the 24 Gy had a 
partial response within 4 weeks of treatment, compared 
to 71  % of patients treated to 16  Gy. Median OS was 
higher in the group treated to 24  Gy than in the group 
treated to 16  Gy, 9 versus 3  months, respectively. The 
most common side effect of treatment was WHO grade 1 
dysphagia, which was experienced by 48 and 43 % of the 
patients treated to 24 and 16 Gy, respectively, and which 
resolved in most patients by 3  weeks after treatment 
(Rodrigues et al. 1993).
From 2000 to 2001 a small, prospective trial tested 
a hypofractioned RT regimen of 12  Gy delivered in 2 
fractions 1 week apart to 23 elderly patients with SVCS. 
Tumor margins of 1–1.5 cm were used and the supraclav-
icular area was not treated. 39 % of patients reported par-
tial symptom relief at 5 days after the first fraction, and 
after the second fraction 74  % of patients reported that 
their symptoms had entirely disappeared. 22 % of patients 
reported treatment-associated nausea, 26  % reported 
WHO grade I–II dysphagia, 17  % reported fatigue, and 
17  % reported systemic symptoms such as chest pain, 
rigors and fevers 12–24 h after the first fraction (Lonardi 
et al. 2002).
Recently, SBRT has become a well-accepted modal-
ity for administering radiation at a variety of anatomical 
sites. Potential benefits of SBRT include a novel bio-
logic rationale for tumor cell kill as well as a decreased 
number of treatments, resulting in decreased treatment 
cost (Timmerman et  al. 2007; Timmerman et  al. 2014). 
Only one manuscript discussing SBRT for SVCS is avail-
able in the current literature (McKenzie et al. 2013). An 
82-year-old man presented with SVCS. Positron emission 
tomography, computed tomography scan, and biopsy 
demonstrated NSCLC metastatic to the right paratra-
cheal lymph nodes with no other detectable sites of 
malignancy. SBRT was used to deliver 50 Gy in 5 fractions 
to the 2.5 cm mediastinal mass. The patient’s symptoms 
improved after the second fraction, and he experienced 
no treatment-related side effects. At 3 months follow-up 
the patient was dyspnea and chest pain free, but he con-
tinued to have visible anterior chest wall collateral ves-
sels (McKenzie et al. 2013). This suggests rapid symptom 
relief and durability of SBRT in this case.
The patient described in the case report was a good 
candidate for SBRT because he had no evidence of 
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metastatic or primary disease at the time of presentation, 
and his obstructing tumor was relatively small. SBRT has 
been shown to have local control rates of up to 97 % in 
early stage NSCLC (Timmerman et al. 2010). Given the 
time necessary to generate an SBRT treatment plan, it is 
not an ideal treatment method for a patient who needs 
rapid symptom palliation. However, for patients with 
potentially curable, reasonably sized tumors that are not 
extremely radiosensitive to conventional therapy but are 
located in anatomically favorable locations, SBRT should 
be included in the list of treatment options.
The literature on hypofractionated RT and SBRT for 
SVCS is not as robust as that for conventionally fraction-
ated RT. However, given the increase in patient conveni-
ence and the decrease in treatment cost associated with 
hypofractionated RT, this may be an area worth investi-
gating in highly select patients, preferably under the aus-
pice of a clinical trial.
Consideration of proton therapy
Protons have a unique energy distribution pattern in tis-
sue compared to photons. Exploiting this difference may 
be beneficial in certain cancer sites, as it may allow for 
higher dose administration to the tumor site with lower 
dose to adjacent, healthy tissues (Mitin and Zietman 
2014). Thus far, however, there is a paucity of high quality 
clinical evidence for efficacy of protons versus photons at 
most disease sites (Olsen et al. 2007; De Ruysscher et al. 
2012). Proton centers are very expensive to build, and 
proton therapy is, at this time, much more costly than 
equivalent photon therapy (Bekelman and Hahn 2014). 
Not all patients are good candidates for proton therapy. 
A scoring system has been proposed to give a framework 
for prioritizing patients that would benefit from proton 
therapy (Bekelman et al. 2014).
One experience of treating SVCS with proton therapy 
has been published. A 66-year-old woman presented with 
a chemoresistant thymic carcinoid tumor that was invad-
ing the cardiac tissue. The patient developed SVCS when 
the tumor reached 15 cm in diameter on chemotherapy. 
Because of the intimacy of the tumor and the normal car-
diac tissue, the decision was made to use proton therapy 
in an attempt to spare normal, adjacent tissues. A dose 
of 74 Gray equivalents (GyE) was delivered in 37 frac-
tions. The patient experienced no acute toxicities, and in 
the months following proton therapy the tumor shrank to 
13 cm. At 2 years follow-up, the tumor had continued to 
decrease in size and the patient exhibited no late toxici-
ties (Sugawara et al. 2014).
In most cases of SVCS, proton therapy offers minimal 
benefit over photon therapy in terms of decreased toxic-
ity and increased efficacy. Proton therapy should only be 
considered in highly select circumstances.
Radiosensitivity
The most common malignant causes of SVCS are 
NSCLC, SCLC and lymphoma, but breast cancer, semi-
noma, malignant thymoma, metastatic colon cancer, 
metastatic renal cell carcinoma, pancreatic cancer, 
Kaposi’s sarcoma, acute myelomonocytic leukemia, leio-
myosarcoma, esophageal carcinoma, childhood tumors, 
thyroid cancer and mesothelioma have all been impli-
cated (Armstrong et al. 1987; Chen et al. 1990; Yellin et al. 
1990; Schraufnagel et  al. 1981; Nicholson et  al. 1997).
These many types of malignancy cover a range of radio-
sensitivity, with lymphoma traditionally being regarded 
as more radiosensitive and renal cell carcinoma less so. 
With the advent of SBRT and other methods of delivering 
high doses of radiation, however, fewer and fewer can-
cers are being considered truly radioresistant (De Meer-
leer et al. 2014). As previously mentioned, RT for SVCS 
should generally be delayed until a histologic diagnosis 
of the cause can be determined (Ampil et al. 2012; Kvale 
et  al. 2007). Usually, determining a histologic diagnosis 
will be more important to guide chemotherapy than RT. 
However, as our understanding of the mechanisms of 
radiosensitivity and radioresistance increases, we may be 
able to make more rational choices as to which patients 
receive RT and which receive other modalities as first-
line treatment (Willers et al. 2013; Lacombe et al. 2013).
Non‑RT treatment modalities
Steroids
No trial or review has ever demonstrated symptomatic 
relief or long-term outcome differences attributable to 
steroid use (Schraufnagel et  al. 1981). However, SVCS 
treatment algorithms often incorporate steroid use as 
prophylaxis against radiation-induced edema, and ster-
oids may be indicated if airway edema is present at the 
time of treatment (Ostler et al. 1997). Recent guidelines 
suggest that if steroids are used in management of SVCS 
then they should be of high potency and limited duration 
(Rowell and Gleeson 2001). Steroids should not be relied 
upon as a primary treatment for SVCS.
Chemotherapy
The role of chemotherapy in management of SVCS 
depends largely on the underlying malignant etiology. For 
chemo-sensitive diseases such as SCLC, non-Hodgkin 
lymphoma and germ cell tumors, chemotherapy should 
be considered a mainstay of treatment (Ostler et  al. 
1997). Indeed, one trial comparing chemotherapy alone 
versus chemotherapy followed by radiation for SVCS due 
to SCLC found no difference in survival between the two 
groups (Spiro et al. 1983). Another trial, however, found 
that SCLC patients who received combined chemora-
diation had a longer time to symptomatic recurrence 
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compared to patients who received chemotherapy 
alone (Chan et al. 1997). A meta-analysis of prospective 
and retrospective studies from 1983 to 1997 found that 
chemotherapy alone (76.9  %), radiation alone (77.6  %) 
and chemoradiation (83.3  %) provided similar rates of 
complete SVCS symptom relief in SCLC patients (Rowell 
and Gleeson 2001). This same meta-analysis found that 
the typical time to symptom alleviation in patients with 
chemo-sensitive disease receiving chemotherapy alone is 
1–2 weeks.
For less chemo-sensitive malignancies such as NSCLC, 
the role of chemotherapy up front is less clear. One trial 
randomizing NSCLC patients to receive either RT alone 
or RT plus chemotherapy was closed before full accrual 
due to increased treatment-associated toxicity in the RT 
plus chemotherapy arm and no difference in outcomes 
between the two groups (Pereira et  al. 1999). A meta-
analysis of prospective and retrospective studies from 
1983 to 1997 found that outcomes were significantly 
worse in treating SVCS in NSCLC patients compared 
to SCLC patients. The rates of complete symptom relief 
were similar in chemotherapy alone (59.0 %) versus radi-
ation alone (63.0 %) but were actually worse in combined 
chemoradiation (31.3  %) (Rowell and Gleeson 2001). It 
should be noticed that the only prospective study exam-
ining combined chemoradiation was the previously men-
tioned trial that closed accrual early, with only sixteen 
patients enrolled in the combined chemoradiation arm 
(Pereira et al. 1999).
A small, prospective trial in the early 1980’s compared 
chemotherapy followed by consolidative radiation to 
chemotherapy alone in 28 SCLC patients with SVCS. 
This study found no difference in SVCS recurrence rates 
between the two trial arms (Spiro et al. 1983).
It should be noted that most studies examining the 
role of chemotherapy in SVCS were conducted prior to 
the advent of targeted biologic therapies. In one case 
report, metastatic sarcoma causing SVCS was treated 
with imatinib and subsequent symptom resolution was 
observed (Maki et  al. 2002). Tyrosine kinase inhibitors 
(TKIs) have been shown to have activity in a variety of 
malignancies (Funakoshi et al. 2014). In the future, TKIs 
may play an increasingly large role in SVCS palliation 
and first line treatment of malignancies where TKI use is 
indicated. No trial has been conducted in the modern era 
of targeted therapy to assess the efficacy or tolerability of 
combined targeted therapy and RT for SVCS.
Stents
Superior vena caval stenting in SVCS was first attempted 
in 1986. Immediate symptom relief was achieved, but 
rates of complications and stent migration were initially 
quite high (Charnsangavej et  al. 1986). In the ensuing 
decades, treatment was refined and new stent materi-
als became available. Today, stent placement is typically 
done using conscious sedation and local anesthesia, 
and can be performed as long as the patient can lie flat 
or semi-supine on the operating table (Watkinson et  al. 
2008; Charnsangavej et  al. 1986). Stent placement is 
quite effective for symptom relief, with up to 97–99 % of 
patients experiencing rapid post-operative relief (Maleux 
et  al. 2013; Gwon et  al. 2013). Headache is typically 
relieved immediately after the procedure, facial edema 
typically resolves within 24  h, and upper extremity and 
truncal edema may last for up to 72 h after stent place-
ment (Hennequin et al. 1995; Rosch et al. 1992). Figure 2 
shows CT images of a patient before and after stent 
placement, and demonstrates the successful resumption 
of SVC flow that had previously been completely blocked 
by a large mediastinal tumor. A recent prospective study 
found that covered stents retained patency longer than 
non-covered stents, with a 12-month patency rate of 94 
versus 48 % for covered versus non-covered, respectively 
(Gwon et al. 2013).
In a retrospective study, 164 consecutive SVCS patients 
receiving stent placement at a single institution from 
1992 to 2007 were examined. 12.8 % of patients experi-
enced treatment-associated complications, and 2.4  % 
died from treatment-associated complications. 21.9  % 
of patients experienced symptom recurrence, but 75  % 
of these patients were successfully treated with restent-
ing (Fagedet et  al. 2013). This experience is in line with 
the findings of a 2006 meta-analysis and a 2014 review 
paper that found percutaneous SVC stenting in the set-
ting of SVCS to have primary patency rates of 64–95 %, 
secondary patency rates of 93–100  %, recurrence rates 
0–40  %, complication rates of 0–25  %, and mortality 
rates of 3–4  % (Uberoi 2006; Rachapalli and Boucher 
2014). Minor complications of stent placement include 
groin hematoma and local infection at puncture site, 
while major complications include stent migration, re-
occlusions of stents, bleeding, cardiac injury, pulmonary 
embolism, pulmonary edema, and pericardial tamponade 
(Rachapalli and Boucher 2014).
Few studies examining hemodynamic changes after 
stent placement are available. One small study includ-
ing five patients looked at hemodynamic changes dur-
ing the first 24  h after surgery. This study found, in all 
five patients, a decreased pressure gradient across the 
caval lesion, an increase in pulmonary capillary wedge 
pressure, and an increase in cardiac output after stent 
placement. By 24 h post-procedure, the pulmonary cap-
illary wedge pressures and cardiac outputs of the five 
patients had returned to near-baseline values, while the 
pressure gradient across the caval lesion continued to 
decline (Yamagami et  al. 2002). All five patients in the 
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hemodynamics study had normal cardiac function, but 
cases of pulmonary edema and heart failure after stent 
placement have been reported in the literature (Kishi 
et  al. 1992, 1993). Presumably, these patients had poor 
cardiac function prior to stent placement, and their car-
diac system was not able to accommodate the increased 
venous return after stent placement (Yamagami et  al. 
2002). Clinicians should consider carefully before pro-
ceeding with stent placement in patients with poor car-
diac function.
Although stenting provides significant, rapid relief of 
SVCS symptoms, it is not usually recommended as first-
line treatment in patients with benign disease or in those 
with long life expectancies, as stent occlusion is likely to 
occur in the months to years following treatment and 
stent placement has some intrinsic risk (Uberoi 2006; 
Rachapalli and Boucher 2014; Watkinson et al. 2008). As 
therapy improves and the average lifespan of an indwell-
ing stent lengthens, however, some authors have argued 
that percutaneous stenting may have a role even in 
benign causes of SVCS (Rizvi et al. 2008). Furthermore, 
stenting may be used when the maximum dose of radia-
tion has been delivered and SVCS symptoms remain or 
recur (Rosch et al. 1992).
Randomized studies comparing stents versus RT or 
chemotherapy are not available. An attempt at doing such 
a study was made at Princess Margaret Hospital without 
success (Wilson et al. 2007).
Radiation therapy and stents
Percutaneously placed stents have become first line 
treatment for most cases of SVCS. For patients with 
malignancy-derived SVCS but with a longer life expec-
tancy, RT and/or chemotherapy may be used with cura-
tive or palliative intent with or without prior stent 
placement.
Most patients with SVCS have an underlying malignant 
cause, and modern treatment usually involves prompt 
stent placement followed by tissue biopsy and subse-
quent RT and/or chemotherapy. One study examined 
149 cancer patients who received stents for palliation of 
SVCS between 1993 and 2008. Most of these patients 
received no treatment before stent placement, but 16.1 % 
received prior chemotherapy, 2.6  % received prior RT 
only, and 6.0  % received prior combined chemoradia-
tion. After treatment, 41.6  % received no further treat-
ment, 29 % received chemotherapy alone, 7.4 % received 
RT alone, and 21.4 % received combined chemoradiation. 
Patients who received chemotherapy or RT alone before 
stenting were more likely to die sooner, while patients 
who received chemoradiation after stenting were more 
likely to live longer (Lanciego et al. 2009). Although this 
retrospective study cannot comment on the relative effi-
cacy of different treatment regimens, it seems that, in 
carefully selected patients, post-stent chemoradiation 
may have some benefit. At the time of this writing there 
are no studies comparing long term patency rates of SVC 
stents in patients who receive RT, chemo, or chemoradia-
tion versus those who do not go on to have further inter-
ventions after stent placement. Case reports of SVCS 
patients receiving further treatment after stent place-
ment suggest that stents may remain patent for months 
to years following RT or chemoradiation (Hamzik et  al. 
2015; Komoda et al. 2012).
Fig. 2 Stent placement for superior vena cava (SVC) syndrome. a Pre‑stenting: SVC occluded by large tumor. White arrow SVC. Black Chevron tumor 
occluding SVC. b Post‑stenting: SVC now patent. White arrow stent in SVC. Black Chevron tumor surrounding SVC
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Stents may be placed after RT. One study found that 
80 % of patient who received stents after RT had further 
symptomatic improvement (Tanigawa et al. 1998).
Outcomes
The development of SVCS does not necessarily directly 
impact OS (Sculier et al. 1986). However, in general, SVCS 
patients have a dismal prognosis. Median survival for all 
SVCS patients ranges from 1.5 to 10 months (Armstrong 
et al. 1987; Schraufnagel et al. 1981; Rowell and Gleeson 
2001; Marcy et al. 2001). 1-year OS is roughly 24 % and 
5-year OS is roughly 9 % (Armstrong et al. 1987). In gen-
eral, patients with benign or infectious causes of SVCS 
fare better than do those with malignancies. The average 
survival of SVCS patients with lung cancer can be as low 
as 5  months, while for those with mediastinal fibrosis it 
can be as high as 9 years (Schraufnagel et al. 1981). There 
have been reports of SVCS patients with NSCLC who 
have survived up to 9  years after RT and patients with 
SCLC who have survived up to 13 years after RT (Nogeire 
et  al. 1979; Percarpio and Gray 1979). For patients who 
have potentially curable disease based on stage and diag-
nosis, all efforts should be made to provide standard of 
care definitive therapy. Of note, long-term survivors of 
SVCS who receive stent placement are at risk for stent 
migration, an uncommon but potentially deadly compli-
cation (Gwon et al. 2013; Martin et al. 2002).
SVCS relapse rates are relatively low after treatment 
with chemotherapy and/or RT. One meta-analysis found 
relapse rates of 17 % in SCLC and 19 % in NSCLC (Row-
ell and Gleeson 2001). Relapse rates following stent 
placement range from 11 to 12 %. Often, recanalization 
is possible after stent failure, resulting in long-term stent 
success rates of greater than 90  % (Rowell and Gleeson 
2001; Nagata et al. 2007).
Areas for future research
Over a decade ago, Rowell and Gleeson published a 
review on SVCS in which they recommended a rand-
omized trial comparing RT to chemotherapy based on 
the histology of the underlying malignancy (Rowell and 
Gleeson 2001). Such a trial has not yet occurred. How-
ever, in the past decade significant advances have been 
made in the treatment of lung cancer. Among other 
changes, targeted agents and SBRT have come into 
widespread use in the treatment of lung cancer. Trials 
are currently exploring the optimal intersection of these 
modalities in lung cancer in general, and the results of 
these trials may impact treatment recommendations for 
SVCS patients.
The published SVCS recurrence rates of almost 20  % 
after chemotherapy and/or RT are from studies published 
in 1983–1997 (Rowell and Gleeson 2001). Presumably, 
treatment outcomes have improved since then, particu-
larly with the advent of combined modality treatments. 
Due to the relatively rare nature of SVCS, completing 
large trials is logistically difficult (Wilson et  al. 2007). 
However, trials looking at outcomes with modern ther-
apy would be useful both in counseling patients and in 
planning therapy. Additionally, trials exploring the ben-
efit of chemotherapy versus targeted therapy and conven-
tional RT versus hypofractionated RT or SBRT should be 
considered, as the efficacy and side effect profile of these 
newer treatment modalities is unknown in SVCS.
Conclusions and recommendations
SVCS causes significant patient distress, usually heralds a 
serious underlying condition, and necessitates expedient 
management. Percutaneous stenting can provide rapid 
symptom relief. Stenting has the additional benefit of 
not altering local tissue and thus allowing for subsequent 
biopsy and histologic diagnosis. Both chemotherapy and 
RT can provide symptom palliation while simultaneously 
addressing systemic disease. Emergent indications for 
immediate therapy include laryngeal and cerebral edema 
and related symptoms, for which endovascular stenting 
followed by RT should be rapidly initiated.
Most patients who present with SVCS should be 
offered prompt stent placement for symptom palliation. 
If the underlying cause of malignancy is not known, this 
should be elucidated. At the discretion of the treating 
physicians, chemotherapy and/or RT can then be offered 
with curative or palliative intent. Some patients may ben-
efit from the increased convenience of a hypofraction-
ated course of RT, although future studies are warranted 
to further refine treatment guidelines.
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